Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04749459
Other study ID # 215232
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 3, 2021
Est. completion date March 31, 2021

Study information

Verified date January 2022
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to determine the SPF of two test materials ChapStick Moisturizer, Classic Flavor and ChapStick Moisturizer, Strawberry Flavor using the methodology described in the International Standard Test Method. This static methodology also meets the requirements of the Australia/New Zealand standard.


Description:

A single-center, randomized, evaluator blind, intra-individual comparison, no treatment and positive controlled clinical study to determine the SPF of two ChapStick sunscreen-containing lip balms as per ISO 24444:2010. For each participant, 4 test sites will have a random assignment number for up to two test materials, control standard, and minimal erythemal dose of unprotected skin (MEDu), with at least 3 of the test sites being utilized for application. All three test sites will be exposed to UV radiation at the expected MED and subsequently evaluated for erythema 16-24 hours after UV exposure.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date March 31, 2021
Est. primary completion date March 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria - Participant must read and execute an informed consent document (that includes a HIPAA statement) indicating that the participant has been informed of all pertinent aspects of the trial before any assessment is performed; - Participant must complete a Medical History Form (MHF) prior to their trial initiation; - Participant must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures; - Participant must agree not to expose their back to additional sunlight or tanning beds, as either can alter the test results; - Participant must agree not to apply any topical skin-care product to the test sites during this trial; - Male or female participants of childbearing potential must agree to use a highly effective method of contraception throughout the trial and for 14 days after the last application of assigned treatment. A participant is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active; - Female participants of childbearing potential must be willing to comply with urine pregnancy testing requirements prior to initiation of trial testing procedures and as may be required for the duration of the trial; - Participant must be considered dependable and capable of understanding and following directions; - Participant must have self-perceived Fitzpatrick skin phototype I, II, or III: Skin Phototype Sunburn and Tanning History I Always burn easily; never tans II Always burns easily; tans minimally III Burns moderately; tans gradually; and - Participant must have an Individual Typology Angle value >28 degrees, determined by the Testing Facility by colorimetric methods, within 1 week of trial participation. Exclusion Criteria - Participant is in ill health as determined by the Principal Investigator; - Participant is an employee of the Clinical Division of the investigational site or a member of their immediate family; - Participant is a GSK CH employee directly involved in the conduct of the trial or a member of their immediate family; - Female participant is pregnant or intending to become pregnant over the duration of the trial or any female participant of childbearing potential who fails to produce a negative urine pregnancy test; - Female participant who is lactating (self-reported); - Participant using medication with photo-sensitizing potential; - Participant has a history of adverse reactions or hypersensitivity to azo dyes, cosmetics, OTC drugs, or other topical personal care products; - Participant taking medications other than birth control that could influence the purpose, integrity or outcome of the trial; - Participant has used topical or systemic steroids, antihistamines, or antibiotics within 7 days of trial initiation or during the trial; - Participant has used anti-inflammatory medications within 7 days of trial initiation or during the trial, that in the opinion of the PI, could interfere with the trial; - Participant has used medication suspected of causing photobiological reactions (e.g., tetracyclines, thiazides, etc.), that has not been taken by the participant through a summer season; - Participant has a dermatological condition; - Participant has a history of abnormal response to the sun, or a condition such as lupus erythematosus or skin cancer; - Participant uses tanning beds frequently; - Participant whose test site was exposed to sunlight within the previous 4 weeks; - Participant has a sunburn, suntan, uneven skin color, visible skin disease, scarring, or tattoo that would interfere with evaluation of test results; Note: The presence of non-dysplastic nevi, blemishes, or moles will be acceptable if, in the PI's judgment, they will neither compromise the clinical trial, nor jeopardize a participant's safety. A participant with dysplastic nevi should be disqualified. - Participant has existing sun damage in the test site; - Participant has excessive hair in the test area and are unwilling to have it clipped; or - Participant whose test sites have been used for clinical testing in which they were exposed to ultraviolet radiation within the past 2 months.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ChapStick Moisturizer, Strawberry Flavor
A single topical application of ChapStick Moisturizer, Strawberry Flavor will be applied to the appropriate 40 square centimeter (cm^2) test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 milligram per centimeter square (mg/cm^2), using 80 +/-2 milligrams (mg) of material.
ChapStick Moisturizer, Classic Flavor
A single topical application of ChapStick Moisturizer, Classic Flavor will be applied to the appropriate 40 cm^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm^2, using 80 +/-2 mg of material.
ISO 24444:2010 P2 Standard Reference Sunscreen
A single topical application of ISO 24444:2010 P2 Standard Sunscreen will be applied to the appropriate 40 cm^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm^2, using 80 +/-2 mg of material.

Locations

Country Name City State
United States GSK Investigational Site Fairfield New Jersey

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values Arithmetic mean of all valid SPFi values of each product on each participant was calculated from the individual Minimal Erythemal Dose (MED) on product treated (MEDp) test sites in relation to unprotected (MEDu) test sites 16-24 hrs after exposure to UVR. SPFi = MEDp/MEDu. No inferential statistical analysis was performed for this outcome. The MED is defined as the lowest dose of UVR that produces the first perceptible unambiguous erythema with defined borders appearing over most of the field of UVR exposure. The UVR exposure should be increased in geometric progression with 25% dose increment in relation to the expected SPF values. All individual SPF values were converted arithmetically to calculate SPF of test material (or control standard). Up to 24 hours post UVR exposure
See also
  Status Clinical Trial Phase
Completed NCT02779270 - Test the Outdoor Usage for Sunscreen Products in Female Adults N/A
Completed NCT02936583 - Sun Protection Factor Assay (SPF Assay 207/2016) N/A
Completed NCT02936544 - Sun Protection Factor Assay (SPF Assay 204/2016) N/A
Completed NCT02936557 - Sun Protection Factor Assay (SPF Assay 205/2016) N/A
Completed NCT02936570 - Sun Protection Factor Assay (SPF Assay 206/2016) N/A
Completed NCT05085327 - Clinical Study to Evaluate the Sun Protection Factor (SPF) of Sunscreen Products N/A
Completed NCT02760563 - 18611 - Sun Protection Factor Assay N/A
Completed NCT02930798 - Sun Protection Factor Assay (SPF Assay 203/2016) N/A
Completed NCT02854137 - Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes N/A
Completed NCT02760576 - 18612 - Sun Protection Factor Assay N/A
Completed NCT02930772 - Sun Protection Factor Assay (SPF Assay 201/2016) N/A
Completed NCT02930746 - Sun Protection Factor Assay (SPF Assay 199/2016) N/A
Completed NCT02930785 - Sun Protection Factor Assay (SPF Assay 202/2016) N/A
Completed NCT02930759 - Sun Protection Factor Assay (SPF Assay 200/2016) N/A
Completed NCT05109104 - Clinical Study to Evaluate the Sun Protection Factor (SPF) of Three Sunscreen Products N/A
Completed NCT04355286 - Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study Phase 1
Completed NCT02962869 - Human Photoallergy Test (824/2016) N/A
Completed NCT02823496 - 18349-Human Photoallergy Test N/A
Completed NCT02823483 - 18348-Human Phototoxicity Test N/A
Completed NCT02962856 - Human Phototoxicity Test (823/2016) N/A